Medpace Holdings, Inc. (Nasdaq: MEDP) reported its financial results for the second quarter of 2025, showing a revenue increase of 14.2% to $603.3 million, compared to $528.1 million in the same period of the previous year. The company also reported a GAAP net income of $90.3 million, or $3.10 per diluted share, up from $88.4 million, or $2.75 per diluted share, in the second quarter of 2024. The net income margin stood at 15.0%, compared to 16.7% in the prior-year period. EBITDA reached $130.5 million, marking a 16.2% increase from $112.3 million in the previous year, with an EBITDA margin of 21.6%. For the year-to-date period ending June 30, 2025, Medpace's revenue totaled $1,161.9 million, reflecting an 11.8% increase from the previous year. The year-to-date GAAP net income was $204.9 million, or $6.79 per diluted share, up from $190.9 million, or $5.96 per diluted share, in the previous year. Year-to-date EBITDA increased by 9.3% to $249.1 million, accounting for 21.4% of revenue. The company reported cash and cash equivalents of $46.3 million as of June 30, 2025, and generated $148.5 million in cash flow from operating activities during the second quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.